Quest Diagnostics unveiled a first-to-market blood test available for consumer purchase that helps assess the potential risk of developing Alzheimer’s disease. In adding AD-Detect, a single-blood-draw ...

Quest Diagnostics unveiled a first-to-market blood test available for consumer purchase that detects and measures the level of per- and polyfluorinated alkyl substances (PFAS), a potentially harmful ...

GRAND RAPIDS, Mich. (WOOD) — PFAS has been making headlines for years now, and based on everything we know about PFAS contamination, it will be several more years before the chemical exposure is ...

Test to be available for clinical and research use as soon as this summer, building on Quest's pioneering blood-based AD-Detect™ product line for assessing symptomatic patients SECAUCUS, N.J., July 9, ...

Quest Diagnostics Inc. said Monday the first blood-based biomarker test to assess the risk of developing Alzheimer’s disease is now available for consumer purchase. The test helps assess the risk of ...

In the June 2024 issue, we explore the ways that artificial intelligence is shaping our economy and culture. The stories and art are about AI—and occasionally by AI. (Throughout the issue, we have ...

Guardant Health (GH) and Quest Diagnostics (DGX) announced a strategic collaboration to make Guardant’s Shield blood-based screening test available to physicians and patients served by Quest in the ...